Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Lung Adenocarcinoma Metastatic: early-phase trial registry

2 of 2 indexed Lung Adenocarcinoma Metastatic trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Lung Adenocarcinoma Metastatic: 2 US clinical trials tracked, 2 recruiting.

Lung Adenocarcinoma Metastatic is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Context Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition lung-adenocarcinoma-metastatic

OPEN 2 | RECR 100% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Lung Adenocarcinoma Meta (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Lung Adenocarcinoma Metastatic

Lung Adenocarcinoma Metastatic lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lung Adenocarcinoma Metastatic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lung Adenocarcinoma Metastatic is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Lung Adenocarcinoma Metastatic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

CT-95 Drug
1 trials
SMART Behavioral
1 trials
Oncology-informed yoga Behavioral
1 trials

US sites by state

Facility locations filed on Lung Adenocarcinoma Metastatic trials. A trial with sites in several states counts in each.

Texas 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
New York 1 trials
New Jersey 1 trials
Michigan 1 trials
Illinois 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lung Adenocarcinoma Metastatic page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Lung Adenocarcinoma Metastatic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Context Therapeutics sponsors the most Lung Adenocarcinoma Metastatic trials on record, review their full trial history before evaluating a specific study. See Context Therapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Adenocarcinoma Metastatic condition card totals 2 registered trials; most-linked intervention CT-95; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.